Comparison of monoamine oxidase inhibition by cigarettes and modified risk tobacco products.
3R4F, reference cigarette
CRP, CORESTA Reference Product
CS, cigarette smoke
DMSO, dimethyl sulfoxide
E-cigarettes
FID, flame ionization detection
GC, gas chromatography
GCW, General Classic White
GVP, gas–vapor phase
Harm reduction
IC50, half maximal inhibitory concentrations
Ki, Inhibition Constant
Km, Michaelis constant
MAO, monoamine oxidases
MESH, electronic cigarette
Monoamine oxidase
PBS, phosphate-buffered saline
PMI, Philip Morris International
PREP, potential reduced exposure products
RT, room temperature
Snus
THS, Tobacco Heating System
TPM, total particulate matter (TPM)
Tobacco heating system
cDNA, complementary DNA
pMRTP, potential modified risk tobacco products
Journal
Toxicology reports
ISSN: 2214-7500
Titre abrégé: Toxicol Rep
Pays: Ireland
ID NLM: 101630272
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
09
2019
revised:
07
11
2019
accepted:
11
11
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
epublish
Résumé
The adverse effects of cigarette smoking are well documented, and the two main strategies for reducing smoking prevalence are prevention of smoking initiation and promotion of smoking cessation. More recently, a third and complementary avenue, tobacco harm reduction has emerged, which is aimed to reduce the burden of smoking-related diseases. This has been enabled by the development of novel products such as electronic cigarettes (e-cigarettes) and heated tobacco products, designed to deliver nicotine with significantly reduced levels of the toxicants that are emitted by cigarettes. Several potential modified risk tobacco products (pMRTP) have been reported to emit significantly less toxicants than cigarettes and significantly reduce toxicant exposure in smokers who switch completely to such products. These are two prerequisites for pMRTPs to reduce harm and the risk of smoking-related disease. However, concerns remain regarding the addictive nature of these products. Smoking addiction is a complex phenomenon involving multiple pharmacological and non-pharmacological factors. Although the main pharmacological substance associated with smoking addiction is nicotine, accumulating evidence suggests that nicotine mostly acts as a primary reinforcer and that other factors are involved in establishing smoking addiction. Inhibition of monoamine oxidases (MAO)-mammalian flavoenzymes with a central role in neurotransmitter metabolism-has also been suggested to be involved in this process. Therefore, we aimed to comparatively investigate the ability of several types of pMRTPs and cigarette smoke (3R4F) to inhibit MAO activity. The results showed that the heated tobacco product Tobacco Heating System (THS) 2.2 and the
Identifiants
pubmed: 31768332
doi: 10.1016/j.toxrep.2019.11.008
pii: S2214-7500(19)30492-5
pmc: PMC6872813
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1206-1215Informations de copyright
© 2019 The Authors. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors report no declarations of interest.
Références
Regul Toxicol Pharmacol. 2016 Nov 30;81 Suppl 2:S27-S47
pubmed: 27720919
Cochrane Database Syst Rev. 2019 Feb 13;2:CD003999
pubmed: 30758045
Med Biol. 1981 Feb;59(1):21-34
pubmed: 7022042
Br Med J. 1976 Jun 12;1(6023):1430-3
pubmed: 953530
Cochrane Database Syst Rev. 2013 May 31;(5):CD009329
pubmed: 23728690
Cochrane Database Syst Rev. 2016 May 09;(5):CD006103
pubmed: 27158893
Chem Res Toxicol. 2001 May;14(5):523-7
pubmed: 11368550
Nicotine Tob Res. 2016 May;18(5):509-23
pubmed: 26508396
Subcell Biochem. 2018;87:117-139
pubmed: 29464559
Comp Biochem Physiol C Toxicol Pharmacol. 2003 Nov;136(3):191-7
pubmed: 14659452
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1205-1211
pubmed: 27832052
Neurosci Lett. 1991 Jun 24;127(2):247-50
pubmed: 1881637
Int J Neuropsychopharmacol. 2001 Mar;4(1):33-42
pubmed: 11343627
Regul Toxicol Pharmacol. 2018 Mar;93:14-33
pubmed: 29080848
Prev Med. 2018 Dec;117:88-97
pubmed: 29944902
Life Sci. 2001 Feb 2;68(11):1231-41
pubmed: 11233991
Eur Neuropsychopharmacol. 2007 Oct;17(10):627-36
pubmed: 17382522
Life Sci. 1997;60(19):1719-27
pubmed: 9129127
Psychopharmacology (Berl). 2007 Feb;190(3):269-319
pubmed: 16896961
Neuropsychopharmacology. 2005 Apr;30(4):705-12
pubmed: 15496937
Annu Rev Public Health. 2018 Apr 1;39:193-213
pubmed: 29323611
Regul Toxicol Pharmacol. 2016 Nov 30;81 Suppl 2:S17-S26
pubmed: 27450400
Neurotoxicology. 2017 Mar;59:22-26
pubmed: 28057462
J Addict Dis. 1998;17(1):23-34
pubmed: 9549600
Lancet. 1988 Jan 16;1(8577):114-5
pubmed: 2891951
Tob Control. 2012 Jan;21(1):39-43
pubmed: 21636610
Addiction. 2004 Jan;99(1):29-38
pubmed: 14678060
Biol Psychiatry. 1995 Dec 1;38(11):756-61
pubmed: 8580230
Chem Res Toxicol. 2008 Nov;21(11):2172-80
pubmed: 19238614
Nature. 1996 Feb 22;379(6567):733-6
pubmed: 8602220
Drug Alcohol Depend. 2015 Oct 1;155:243-52
pubmed: 26257022
Science. 1981 Oct 30;214(4520):573-5
pubmed: 7291998
N Engl J Med. 2019 Feb 14;380(7):629-637
pubmed: 30699054
Neurotoxicology. 2003 Jan;24(1):75-82
pubmed: 12564384
Neurotox Res. 2002 Mar;4(2):151-60
pubmed: 12829416
Chem Res Toxicol. 2000 Jan;13(1):31-5
pubmed: 10649964
Biochem Biophys Res Commun. 2005 Jan 14;326(2):378-86
pubmed: 15582589
Life Sci. 1981 Dec 14;29(24):2511-8
pubmed: 7321773
J Clin Psychopharmacol. 2009 Feb;29(1):86-8
pubmed: 19142115
Bioorg Med Chem. 2006 May 15;14(10):3392-8
pubmed: 16458520
Int J Neuropsychopharmacol. 2009 Nov;12(10):1355-66
pubmed: 19366487
Multidiscip Respir Med. 2014 Feb 04;9(1):9
pubmed: 24495744
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14065-9
pubmed: 8943061
Jpn J Pharmacol. 1989 Jan;49(1):151-3
pubmed: 2724679
Eur J Pharmacol. 1996 Oct 24;314(1-2):75-82
pubmed: 8957221
Epigenetics. 2012 Oct;7(10):1151-60
pubmed: 22948232
Nat Genet. 2019 Feb;51(2):237-244
pubmed: 30643251
Nicotine Tob Res. 1999 Dec;1(4):325-9
pubmed: 11072429
Alcohol Clin Exp Res. 2003 Mar;27(3):440-9
pubmed: 12658109